Ibrutinib in treatment for refractory or relapsed CLL
Are combination therapies more effective for the treatment of relapsed refractory CLL?
Navigating advances in the myeloma landscape over the past couple of years
Saad Z. Usmani
How will biosimilars save us money?
What we are learning about CLL treatments and the microenvironment